Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization
Importance
Testosterone treatment is a necessary component of care for some transgender and gender-diverse individuals. Observational studies have reported associations between commencement of gender-affirming hormone therapy and improvements in gender dysphoria and depression, but there is a lack of data from randomized clinical trials.
Objective
To assess the effect of testosterone therapy compared with no treatment on gender dysphoria, depression, and suicidality in transgender and gender-diverse adults seeking masculinization.
Design, Setting, and Participants
A 3-month open-label randomized clinical trial was conducted at endocrinology outpatient clinics and primary care clinics specializing in transgender and gender-diverse health in Melbourne, Australia, from November 1, 2021, to July 22, 2022. Participants included transgender and gender-diverse adults aged 18 to 70 years seeking initiation of testosterone therapy.
Interventions
Immediate initiation of testosterone commencement (intervention group) or no treatment (standard care waiting list of 3 months before commencement). This design ensured no individuals would be waiting longer than the time to standard care.
Main Outcomes and Measures
The primary outcome was gender dysphoria, as measured by the Gender Preoccupation and Stability Questionnaire. Secondary outcomes included the Patient Health Questionnaire-9 (PHQ-9) to assess depression and the Suicidal Ideation Attributes Scale (SIDAS) to assess suicidality. Questionnaires were undertaken at 0 and 3 months. The evaluable cohort was analyzed.
Results
Sixty-four transgender and gender-diverse adults (median [IQR] age, 22.5 [20-27] years) were randomized. Compared with standard care, the intervention group had a decrease in gender dysphoria (mean difference, −7.2 points; 95% CI, −8.3 to −6.1 points; P < .001), a clinically significant decrease in depression (ie, change in score of 5 points on PHQ-9; mean difference, −5.6 points; 95% CI, −6.8 to −4.4 points; P < .001), and a significant decrease in suicidality (mean difference in SIDAS score, −6.5 points; 95% CI, −8.2 to −4.8 points; P < .001). Resolution of suicidality assessed by PHQ-9 item 9 occurred in 11 individuals (52%) with immediate testosterone commencement compared with 1 (5%) receiving standard care (P = .002). Seven individuals reported injection site pain/discomfort and 1 individual reported a transient headache 24 hours following intramuscular administration of testosterone undecanoate. No individual developed polycythemia.
Conclusions and Relevance
In this open-label randomized clinical trial of testosterone therapy in transgender and gender-diverse adults, immediate testosterone compared with no treatment significantly reduced gender dysphoria, depression, and suicidality in transgender and gender-diverse individuals desiring testosterone therapy.
Trial Registration
ANZCTR Identifier:
Top-30
Journals
|
1
2
3
4
|
|
|
International Journal of Transgender Health
4 publications, 11.11%
|
|
|
Internal Medicine Journal
3 publications, 8.33%
|
|
|
EClinicalMedicine
2 publications, 5.56%
|
|
|
European Journal of Endocrinology
1 publication, 2.78%
|
|
|
Social Science and Medicine
1 publication, 2.78%
|
|
|
Annals of Neurology
1 publication, 2.78%
|
|
|
Current Obstetrics and Gynecology Reports
1 publication, 2.78%
|
|
|
Anaesthesia
1 publication, 2.78%
|
|
|
BMJ Oncology
1 publication, 2.78%
|
|
|
Medical Journal of Australia
1 publication, 2.78%
|
|
|
Endocrine Practice
1 publication, 2.78%
|
|
|
Journal of Clinical Endocrinology and Metabolism
1 publication, 2.78%
|
|
|
JAMA network open
1 publication, 2.78%
|
|
|
Nature Reviews Neurology
1 publication, 2.78%
|
|
|
Clinical Chemistry
1 publication, 2.78%
|
|
|
Journal of Medical Internet Research
1 publication, 2.78%
|
|
|
ANZ Journal of Surgery
1 publication, 2.78%
|
|
|
Clinical Endocrinology
1 publication, 2.78%
|
|
|
Psiquiatria Biologica
1 publication, 2.78%
|
|
|
Blood advances
1 publication, 2.78%
|
|
|
Ca-A Cancer Journal for Clinicians
1 publication, 2.78%
|
|
|
American Journal of Bioethics
1 publication, 2.78%
|
|
|
Journal of Assisted Reproduction and Genetics
1 publication, 2.78%
|
|
|
Drug Metabolism and Disposition
1 publication, 2.78%
|
|
|
Nature Medicine
1 publication, 2.78%
|
|
|
Thrombosis Research
1 publication, 2.78%
|
|
|
PLoS ONE
1 publication, 2.78%
|
|
|
Implementation Science Communications
1 publication, 2.78%
|
|
|
Indian Journal of Endocrinology and Metabolism
1 publication, 2.78%
|
|
|
1
2
3
4
|
Publishers
|
1
2
3
4
5
6
7
8
9
|
|
|
Wiley
9 publications, 25%
|
|
|
Elsevier
7 publications, 19.44%
|
|
|
Taylor & Francis
5 publications, 13.89%
|
|
|
Springer Nature
5 publications, 13.89%
|
|
|
Oxford University Press
2 publications, 5.56%
|
|
|
BMJ
1 publication, 2.78%
|
|
|
The Endocrine Society
1 publication, 2.78%
|
|
|
American Medical Association (AMA)
1 publication, 2.78%
|
|
|
JMIR Publications
1 publication, 2.78%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 2.78%
|
|
|
American Society of Hematology
1 publication, 2.78%
|
|
|
Public Library of Science (PLoS)
1 publication, 2.78%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.78%
|
|
|
1
2
3
4
5
6
7
8
9
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.